License and collaboration agreements - Additional Information (Detail) - USD ($)
|
|
|
1 Months Ended |
12 Months Ended |
|
Jun. 25, 2020 |
Dec. 19, 2018 |
Jun. 30, 2020 |
Apr. 30, 2020 |
Dec. 31, 2021 |
Dec. 31, 2020 |
Jun. 30, 2018 |
| Expense related to milestone payments |
|
|
|
|
$ 0
|
$ 0
|
|
| KU Leuven [Member] |
|
|
|
|
|
|
|
| Collaboration expire period |
2 years 6 months
|
|
|
|
|
|
|
| Emory license agreement [Member] | Emory university [Member] |
|
|
|
|
|
|
|
| Non-refundable payment |
|
|
$ 150,000
|
|
|
|
|
| Long term purchase commitment additional obligation to be paid |
|
|
35,000
|
|
|
|
|
| Research plan funding amount |
|
|
$ 270,000
|
|
|
|
|
| Research plan expiry period |
|
|
1 year
|
|
|
|
|
| Long term purchase commitment period description |
|
|
|
|
The research plan terminates one year from the effective date, with the Company having an option to extend for a second year
|
|
|
| Expense related to milestone payments |
|
|
|
|
$ 195,000
|
4,500,000
|
|
| Payments for royalties |
|
|
|
|
0
|
0
|
|
| Emory license agreement [Member] | Emory university [Member] | Maximum [Member] |
|
|
|
|
|
|
|
| Aggregate payments |
|
|
|
|
|
|
$ 125,000,000.0
|
| Luxna license agreement [Member] | Luxna biotech Co Ltd [Member] |
|
|
|
|
|
|
|
| Expense related to milestone payments |
|
|
|
|
500,000
|
0
|
|
| Payments for royalties |
|
|
|
|
$ 0
|
0
|
|
| Luxna license agreement [Member] | Luxna biotech Co Ltd [Member] | Maximum [Member] |
|
|
|
|
|
|
|
| Aggregate payments |
|
$ 55,500,000
|
|
|
|
|
|
| Luxna license agreement [Member] | Research and Development [Member] | Luxna biotech Co Ltd [Member] |
|
|
|
|
|
|
|
| Upfront license fees paid |
|
$ 600,000
|
|
|
|
|
|
| Non-refundable payment |
|
|
|
$ 200,000
|
|
|
|
| Katholieke Universiteit Leuven License Agreement [Member] | Katholieke Universiteit Leuven [Member] |
|
|
|
|
|
|
|
| Non-refundable payment |
$ 30,000,000.0
|
|
|
|
|
|
|
| Long term purchase commitment period description |
|
|
|
|
Unless terminated earlier by either party, the agreement shall continue until the expiration of the last to expire royalty term, which is the later of the expiration or termination of the last valid patent claim covering the manufacture, use, sale or importation of the licensed product in a particular country or 10 years after the first commercial sale of a licensed product.
|
|
|
| First commercial sale of a licensed product period |
10 years
|
|
|
|
|
|
|
| Katholieke Universiteit Leuven License Agreement [Member] | Katholieke Universiteit Leuven [Member] | Maximum [Member] |
|
|
|
|
|
|
|
| Non-refundable payment |
$ 32,000,000.0
|
|
|
|
|
|
|
| Merck License and Research Collaboration | Merck |
|
|
|
|
|
|
|
| Revenue recognized from collaborative arrangements |
|
|
|
|
$ 4,400,000
|
0
|
|
| Merck License and Research Collaboration | Merck | Maximum [Member] |
|
|
|
|
|
|
|
| Milestone payments and royalties receivable |
|
|
|
|
|
$ 458,000,000.0
|
|